Antisense makes sense for Doreen

From an uncharacteristically sensible portfolio, the one speccy stock in there - Antisense Therapeutics (a name likely to give even the most hardened investor pause, although quite apt in the case of Doreen) - has added more than $10,000 to Ms Daze's pile. There wasn't any sense in the share price spike, either: the company told the ASX it didn't know why its shares jumped so sharply.

Anyway, that was enough to pip a chartist who was desperate for a return to winning ways. Richard Pritchard led from the start but couldn't match the late dash from Doreen. Heartbroken, Richard returns to his cave for a much-needed piece of Excel therapy.

Reader Gary Scott was the best of the rest and claims a credible third spot. He made 6.1 per cent on his money overall, better than the top 200's 3.5 per cent. His picks of Fortescue, Iluka and Rio did well in a race where resource stocks outperformed.

Despite a weak final week, Pottsy finishes in the top half of the table, beating off a late surge from nurse Denise Borthwick, who, aside from Doreen, was the standout performer during the final leg thanks to Lynas Corp.

Retired valuer Jim Gracie only slightly underperformed the market, while year 7 student Rafael Ungar's stocks showed decidedly mixed returns, which is the story of the market, really. Next week: a new race!

Patrick Commins